Ceritinib

BNF:: Immune system and malignant disease
Status:: Red
Decision Date:: July 2016

Comments

RED:

NICE TA395: for previously treated anaplastic lymphoma kinase positive non-small cell lung cancer. (Decision date - July 2016).
NICE TA500: for untreated ALK- positive non-small cell lung cancer. (Decision date - February 2018).

NHS England drug. To be used in line with NHSE commissioning intentions.

Red Drug Classifications

1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)